A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain

A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain

Researchers have published a structured plan for a secure and intelligent drug delivery model integrating neural networks with blockchain technology — a convergence that could reshape how pharmaceutical companies approach data integrity, supply chain transparency, and regulatory compliance. For BD teams and analysts tracking digital health infrastructure, the implications are immediate and far-reaching.

Key Takeaways

• A proposed blockchain-based solution (BPSCM) implements drug delivery across three phases — registration, pharmaceutical product circulation, and secure payment — using smart contracts and cryptographic operators to ensure data provenance.
• Neural networks enable more accurate analysis of complex medical data, while blockchain provides decentralized, tamper-resistant storage of medical records and drug delivery information.
• The integrated framework significantly improves data integrity, reduces compliance risks, and streamlines regulatory processes — a combination that directly addresses FDA and EMA priorities around supply chain security.
• Security analysis demonstrates the model effectively mitigates impersonation and collusion attacks, two persistent vulnerabilities in traditional pharmaceutical supply chain management.

What happened?

A peer-reviewed study published in Heliyon in November 2024 by Adla Padma and Mangayarkarasi Ramaiah of the Vellore Institute of Technology detailed a blockchain-based solution for secure information sharing in pharmaceutical supply chain management (BPSCM). The model is implemented in three distinct phases: registration, pharmaceutical product circulation, and secure payment.

During the registration phase, the system computes identification numbers using hashed private keys combined with the Edwards-curve digital signature algorithm (EdDSA) for all stakeholders. The pharmaceutical product circulation phase executes transactions among participants through smart contracts, with cryptographic operators ensuring data provenance at every node. The secure payment phase closes the loop with verified, auditable financial exchanges.

The security analysis accompanying the framework demonstrates that it effectively mitigates impersonation and collusion attacks — two attack vectors that have historically plagued pharmaceutical logistics. Performance metrics including gas consumption, throughput, latency, and computational cost were evaluated, though specific benchmark figures were not disclosed in the published abstract.

This work sits within a broader wave of research. A 2025 study by RM Alhazmi proposed a Hybrid Deep Neural Network model (DTPCCM-HDNN) for digital transformation in pharmaceutical cold chain management. Separately, MA Mohammed and colleagues introduced BDAFL DNN, a blockchain-integrated data analytics framework combining Federated Learning and Deep Neural Networks for real-time healthcare applications. A 2020 paper by K Abbas — cited 474 times — proposed a blockchain and machine learning-based drug supply chain management and recommendation system (DSCMR), establishing early precedent for this convergence.

What does it mean for pharma BD and regulatory teams?

The integration of neural networks with blockchain technology offers a decentralized, tamper-proof solution for tracking and verifying drug authenticity — a capability that directly responds to the FDA's ongoing focus on supply chain security under the Drug Supply Chain Security Act (DSCSA). The FDA's drug supply chain integrity program has increasingly emphasized interoperable, electronic tracking systems, and a model combining AI-driven analytics with immutable ledger technology aligns squarely with that trajectory.

For business development teams evaluating partnership or acquisition targets in digital pharma infrastructure, this class of technology represents a competitive differentiator. Companies that can demonstrate tamper-resistant, auditable drug delivery records will hold an advantage in regulatory submissions and tenders — particularly in the European market, where the EMA's good manufacturing practice requirements demand rigorous documentation of product provenance and handling.

The compliance angle is equally significant. The integration of blockchain and AI has been shown to significantly improve data integrity, reduce compliance risks, and streamline regulatory processes. For companies navigating the FDA's guidance on data integrity and compliance with cGMP, a system that cryptographically secures every transaction and uses neural networks to flag anomalies in real time could materially reduce inspection risk and the cost of remediation.

From a competitive benchmarking perspective, the question is no longer whether AI and blockchain will converge in pharmaceutical logistics — it is which companies will operationalize the integration first. The research published to date remains largely academic, but the architectural blueprints are sufficiently detailed to inform commercial development. BD teams should monitor patent filings and early-stage startups working at this intersection, as the window for strategic positioning is narrowing.

Frequently Asked Questions

Related coverage

• $2M Gene Therapy Cures Need a Financing Model
• FDA approves Vertex’s Journavx as first non-opioid pain drug for acute pain
• Biogen and Eisai expand Leqembi access with subcutaneous maintenance dosing